LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 25

Search options

  1. Article: Is intent-to-treat analysis always (ever) enough?

    Sheiner, Lewis B

    British journal of clinical pharmacology

    2002  Volume 54, Issue 2, Page(s) 203–211

    MeSH term(s) Clinical Trials as Topic/methods ; Clinical Trials as Topic/standards ; Humans ; Patient Compliance ; Patient Dropouts ; Research Design
    Language English
    Publishing date 2002-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1046/j.1365-2125.2002.01628.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Analyzing multi-response data using forcing functions.

    Zhang, Liping / Sheiner, Lewis B

    Journal of pharmacokinetics and pharmacodynamics

    2005  Volume 32, Issue 2, Page(s) 283–305

    Abstract: Introduction: Two analytic strategies can be taken to the analysis of multi-response data: a multivariate output model can be fit to all the response components simultaneously (SIM), or each response component can be fit separately to a univariate ... ...

    Abstract Introduction: Two analytic strategies can be taken to the analysis of multi-response data: a multivariate output model can be fit to all the response components simultaneously (SIM), or each response component can be fit separately to a univariate output model, conditioning in some way on the non-modeled components, the so-called forcing function approach (FFA). Focusing on a special case of multi-response model corresponding to a (pharmacokinetic) physiological f low model (PFM), the aims of this study are to (i) provide an algorithm for applying FFA to multi-response data from a PFM; (ii) examine the performance of FFA vs. SIM under optimal conditions for both, and in the presence of model misspecification; (iii) make recommendations regarding the use of FFA for multi-response data analysis.
    Methods: The basic PFM we use (variants of the basic model are used for simulation) has four homogenous compartments among which drug distributes. All are sampled arterial blood (A), non-eliminating tissue (N), eliminating tissue (E), and venous blood (V), which is also the drug dosing site. Parameters are blood f low rates to E and N, volumes of distribution of A, E, N, and V, elimination rate constant from E, and observation error variances. Observations from a generic individual under various study designs and parameter values are simulated. Using data-analytic models (DAM) both the same as, and different than the data simulation model (DSM), SIM fits the PFM to all data simultaneously; FFA first fits each type of response (one per tissue) separately, approximating the tissue's input by linearly interpolating the observed concentrations from the donor tissue(s), estimates the identifiable parameter combinations for the response type, and then solves the simultaneous equations linking these across tissues, to obtain the primary model parameters of interest. This simulation and analysis steps are repeated to generate reliable performance statistics. Performances are compared with respect to parameter estimation error (when DAM and DSM are identical), and interpolated prediction error (when DAM and DSM are/are-not identical). The ability of SIM and FFA to identify the correct analytic model is also examined by comparing their failure rates in rejecting the wrong DAM.
    Results: The parameter estimation errors with FFA are generally about two times greater than those with SIM when the DAM is identical to the DSM. The prediction errors of FFA are about ten times greater than those of SIM when the DAM is identical to the DSM, and are about three times greater when the two are different. However, SIM fails to identify the correct model twice as often as FFA.
    Conclusions: Despite its greater convenience for model building, and its clear advantages for model identification, FFA's final parameter estimates cannot be trusted when the multi-response system being modeled involves feedback. The size of the ratio of the two FFA residuals (obtained from the response-specific fits and from predictions made with the final FFA parameters) can, however, be used to indicate when FFA's final estimates may be trustworthy.
    MeSH term(s) Algorithms ; Computer Simulation ; Data Interpretation, Statistical ; Humans ; Models, Statistical ; Multivariate Analysis ; Pharmacokinetics ; Physiology/statistics & numerical data ; Predictive Value of Tests ; Reproducibility of Results
    Language English
    Publishing date 2005-04
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2041601-5
    ISSN 1573-8744 ; 1567-567X
    ISSN (online) 1573-8744
    ISSN 1567-567X
    DOI 10.1007/s10928-005-0065-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods.

    Kenna, Leslie A / Sheiner, Lewis B

    Statistics in medicine

    2004  Volume 23, Issue 23, Page(s) 3561–3580

    Abstract: Non-compliance with the nominal prescribed dosage causes unintended variability in actual drug exposure during clinical trials. In the ideal case that compliance is not a confounder, and it is known--hence actual dosage is known--true dose-response can ... ...

    Abstract Non-compliance with the nominal prescribed dosage causes unintended variability in actual drug exposure during clinical trials. In the ideal case that compliance is not a confounder, and it is known--hence actual dosage is known--true dose-response can be validly estimated. Measuring compliance presents a challenge, however. A simulation study of the case that dosage history questionnaires (C(Q)--usually over-optimistic estimates of actual compliance) are available in all subjects enrolled in a clinical trial, but accurate compliance measurements (C--e.g. from electronic medication event monitors), are only available in a (random) fraction of subjects is reported. It reveals that a 'Maximum Penalized Marginal Likelihood' (MPML) method which uses all compliance data, effectively calibrating C(Q) to C, is superior to other methods which use only one compliance measure, or both, or neither (neither = ITT, intention to treat, which assumes actual dosage equals nominal dosage), but do not calibrate. MPML yields the most precise estimates of dose-response over widely varying clinical trial designs, extremes in quality and quantity of compliance information, and a range of drug effect sizes. It is most beneficial when compliance data are sparse and maintains good performance even when its key assumptions are somewhat violated.
    MeSH term(s) Algorithms ; Biometry/methods ; Clinical Trials as Topic/statistics & numerical data ; Data Interpretation, Statistical ; HIV Infections/drug therapy ; HIV Protease Inhibitors/administration & dosage ; Homeless Persons ; Humans ; Likelihood Functions ; Patient Compliance/statistics & numerical data ; Pharmaceutical Preparations/administration & dosage ; Self Administration/statistics & numerical data
    Chemical Substances HIV Protease Inhibitors ; Pharmaceutical Preparations
    Language English
    Publishing date 2004-12-15
    Publishing country England
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 843037-8
    ISSN 1097-0258 ; 0277-6715
    ISSN (online) 1097-0258
    ISSN 0277-6715
    DOI 10.1002/sim.1830
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Reply.

    Sheiner, Lewis B. / Rubin, Donald B.

    Clinical pharmacology and therapeutics

    2000  Volume 68, Issue 6, Page(s) 688–689

    Language English
    Publishing date 2000-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: More efficient clinical trials through use of scientific model-based statistical tests.

    Jonsson, E Niclas / Sheiner, Lewis B

    Clinical pharmacology and therapeutics

    2002  Volume 72, Issue 6, Page(s) 603–614

    MeSH term(s) Clinical Trials, Phase III as Topic/standards ; Drug Approval/methods ; Humans ; Models, Statistical ; Patient Selection ; Random Allocation ; Severity of Illness Index ; United States
    Language English
    Publishing date 2002-12
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1067/mcp.2002.129307
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Diagnostics for confounding in PK/PD models for oxcarbazepine.

    Nedelman, Jerry R / Rubin, Donald B / Sheiner, Lewis B

    Statistics in medicine

    2007  Volume 26, Issue 2, Page(s) 290–308

    Abstract: One type of pharmacokinetic/pharmacodynamic (PK/PD) relationship that is used to characterize the therapeutic action of a drug is the relationship between some univariate summary of the plasma-concentration-versus-time profile and the drug effect on a ... ...

    Abstract One type of pharmacokinetic/pharmacodynamic (PK/PD) relationship that is used to characterize the therapeutic action of a drug is the relationship between some univariate summary of the plasma-concentration-versus-time profile and the drug effect on a response outcome. Operationally, such a relationship may be observed in a large clinical trial where randomly sampled patients are randomized to different values of the concentration summary. If, under such conditions, the relationship between concentration and effect does not depend on the dose needed to attain the target concentration, such a relationship will be called a true PK/PD relationship. When the true PK/PD relationship is assessed as an object of estimation in a dose-controlled clinical trial (i.e. when dose is randomized), observed drug concentration is an outcome variable. The estimated PK/PD relationship between observed outcome and observed concentration, which we then refer to as the conventional PK/PD relationship, may be biased for the true PK/PD relationship. Because of this bias, the conventional relationship is called confounded for the true one. We show that diagnostics for confounding can be devised under reasonable assumptions. We then apply these diagnostics to PK/PD assessments of adults and children on oxcarbazepine adjunctive therapy. It was necessary to demonstrate the similarity of the true PK/PD relationships of adults and children on adjunctive therapy in order to support the approval of oxcarbazepine monotherapy in children by a bridging argument.
    MeSH term(s) Adult ; Anticonvulsants/blood ; Anticonvulsants/pharmacokinetics ; Anticonvulsants/pharmacology ; Carbamazepine/analogs & derivatives ; Carbamazepine/blood ; Carbamazepine/pharmacokinetics ; Carbamazepine/pharmacology ; Child ; Dose-Response Relationship, Drug ; Humans ; Models, Biological ; Randomized Controlled Trials as Topic ; Seizures/drug therapy ; Seizures/metabolism
    Chemical Substances Anticonvulsants ; Carbamazepine (33CM23913M) ; oxcarbazepine (VZI5B1W380)
    Language English
    Publishing date 2007-01-30
    Publishing country England
    Document type Journal Article
    ZDB-ID 843037-8
    ISSN 1097-0258 ; 0277-6715
    ISSN (online) 1097-0258
    ISSN 0277-6715
    DOI 10.1002/sim.2542
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Conference proceedings: Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.

    Stanski, Donald R / Rowland, Malcolm / Sheiner, Lewis B

    Journal of pharmacokinetics and pharmacodynamics

    2005  Volume 32, Issue 2, Page(s) 199–211

    Abstract: This report highlights the main points emerging from a meeting sponsored on "Getting the Dose Right" in clinical development, jointly sponsored by the European Federation of Pharmaceutical Sciences and the European Center of Pharmaceutical Medicine, as ... ...

    Abstract This report highlights the main points emerging from a meeting sponsored on "Getting the Dose Right" in clinical development, jointly sponsored by the European Federation of Pharmaceutical Sciences and the European Center of Pharmaceutical Medicine, as part of the Workshop Series on Frontiers in Drug Development, in Basel, Switzerland on December 9-12, 2002.
    MeSH term(s) Clinical Trials as Topic ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical ; Drug Industry ; Europe ; Legislation, Drug ; Pharmaceutical Preparations/administration & dosage ; United States
    Chemical Substances Pharmaceutical Preparations
    Language English
    Publishing date 2005-04
    Publishing country United States
    Document type Congresses
    ZDB-ID 2041601-5
    ISSN 1573-8744 ; 1567-567X
    ISSN (online) 1573-8744
    ISSN 1567-567X
    DOI 10.1007/s10928-005-0010-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.

    Peck, Carl C / Rubin, Donald B / Sheiner, Lewis B

    Clinical pharmacology and therapeutics

    2003  Volume 73, Issue 6, Page(s) 481–490

    MeSH term(s) Biomarkers ; Clinical Trials as Topic/statistics & numerical data ; Drug Approval/methods ; Humans ; Legislation, Drug/trends ; Randomized Controlled Trials as Topic/statistics & numerical data ; United States ; United States Food and Drug Administration
    Chemical Substances Biomarkers
    Language English
    Publishing date 2003-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1016/S0009-9236(03)00018-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Determination of maximum effect.

    Sheiner, Lewis B / Holford, Nicholas H G

    Clinical pharmacology and therapeutics

    2002  Volume 71, Issue 4, Page(s) 304; author reply 304–5

    MeSH term(s) Chondroitin Sulfates/pharmacokinetics ; Chondroitin Sulfates/pharmacology ; Humans
    Chemical Substances Chondroitin Sulfates (9007-28-7)
    Language English
    Publishing date 2002-04
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1067/mcp.2002.122277
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

    Zhang, Liping / Beal, Stuart L / Sheiner, Lewis B

    Journal of pharmacokinetics and pharmacodynamics

    2004  Volume 30, Issue 6, Page(s) 387–404

    Abstract: Dose [-concentration]-effect relationships can be obtained by fitting a predictive pharmacokinetic (PK)-pharmacodynamic (PD) model to both concentration and effect observations. Either a model can befit simultaneously to all the data ("simultaneous" ... ...

    Abstract Dose [-concentration]-effect relationships can be obtained by fitting a predictive pharmacokinetic (PK)-pharmacodynamic (PD) model to both concentration and effect observations. Either a model can befit simultaneously to all the data ("simultaneous" method), or first a model can befit to the PK data and then a model can be fit to the PD data, conditioning in some way on the PK data or on the estimates of the PK parameters ("sequential" method). Using simulated data, we compare the performance of the simultaneous method with that of three sequential method variants with respect to computation time, estimation precision, and inference. Using NONMEM, under various study designs, observations of one type of PK and one type of PD response from different numbers of individuals were simulated according to a one-compartment PK model and direct Emax PD model, with parameters drawn from an appropriate population distribution. The same PK and PD models were fit to these observations using simultaneous and sequential methods. Performance measures include computation time,fraction of cases for which estimates are successfully obtained, precision of PD parameter estimates, precision of PD parameter standard error estimates, and type-I error rates of a likelihood ratio test. With the sequential method, computation time is less, and estimates are more likely to be obtained. Using the First Order Conditional Estimation (FOCE) method, a sequential approach that conditions on both population PK parameter estimates and PK data, estimates PD parameters and their standard errors about as well as the "gold standard" simultaneous method, and saves about 40% computation time. Type-I error rates of likelihood ratio test for both simultaneous and sequential approaches are close to the nominal rates.
    MeSH term(s) Computer Simulation ; Data Interpretation, Statistical ; Dose-Response Relationship, Drug ; Drug Evaluation/methods ; Models, Biological ; Pharmacokinetics ; Pharmacology ; Research Design ; Time Factors
    Language English
    Publishing date 2004-01-01
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 2041601-5
    ISSN 1573-8744 ; 1567-567X
    ISSN (online) 1573-8744
    ISSN 1567-567X
    DOI 10.1023/b:jopa.0000012998.04442.1f
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top